Skip to content

Live Events

Live Events

Live Events

Live Events

MEC Basic Full List View

By pinki@katapult.biz / February 16, 2025

MEC Basic

Events

Speciality

Type of Media

Author / Speaker

Title

Search Entries:

«
1
…
40
41
42
43
44
…
66
»

Latest Treatments in Triple Negative Breast Cancer

Latest Treatments in Triple Negative Breast Cancer

Hope Rugo, MD, FASCO

Updates on ER+ Breast Cancer

Updates on ER+ Breast Cancer

Joseph A. Sparano, MD, FACP

New Developments in HER2+ Breast

New Developments in HER2+ Breast

Mark Pegram, MD

Immunotherapy in Kidney & Bladder Cancer

Immunotherapy in Kidney & Bladder Cancer

Primo N. Lara Jr.,MD

Toxicities in Immunotherapy

Toxicities in Immunotherapy

Lisa Kottschade, APRN, MSN, CNP

Role of Interventional Radiology in Oncology Care

Role of Interventional Radiology in Oncology Care

Brian F Baigorri, MD, RPVI

Biosimilars Implementation in the United States: Where Opportunities Remain

Biosimilars Implementation in the United States: Where Opportunities Remain

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE

Advances in the Treatment of CNS Malignancies

Advances in the Treatment of CNS Malignancies

Frances Chow, MD

SCLC Case

Marie Suga, MD, MPH

Stage IV KRAS Mutant Lung Cancer Case

Stage IV KRAS Mutant Lung Cancer Case

Jonathan W. Riess, MD, MS

EGFR-Mutated Lung Cancers

EGFR-Mutated Lung Cancers

Collin Blakely, MD, PhD

Immunotherapy

David R. Gandara, MD.

What to do About ONJ in the Osteoporosis Patient?

What to do About ONJ in the Osteoporosis Patient?

Robert E. Marx, DDS, FACS

Updates in Esophageal and Gastric Cancers

Updates in Esophageal and Gastric Cancers

Caio Rocha Lima, MD

Breast Cancer Cases

Breast Cancer Cases

Delia Guaqueta, MD

Inhibiting CDK4/6, PIK3CA, and PARP in mBC

Inhibiting CDK4/6, PIK3CA, and PARP in mBC

Stephanie Graff, MD

Endocrine Therapy in the Neoadjuvant and Adjuvant Setting: ER+ HER-2 Normal Node Negative and Node Positive Breast Cancer

Endocrine Therapy in the Neoadjuvant and Adjuvant Setting: ER+ HER-2 Normal Node Negative and Node Positive Breast Cancer

Vicente Valero, MD

The Management of HER2+ Breast Cancer: A Rapidly Changing Frontier

The Management of HER2+ Breast Cancer: A Rapidly Changing Frontier

Jane Meisel, MD

Breast Cancer Immunotherapy

Breast Cancer Immunotherapy

Joyce O'Shaughnessy, MD

Updates in Stem Cell Transplantation and CAR-T Therapy for Heme Malignancies

Updates in Stem Cell Transplantation and CAR-T Therapy for Heme Malignancies

Krishna Komanduri, MD

Chronic Lymphocytic Leukemia: Practice Updates in Treatment-Naive and Relapse Disease

Chronic Lymphocytic Leukemia: Practice Updates in Treatment-Naive and Relapse Disease

Jose Sandoval-Sus, MD

B-Cell Lymphomas: Updates and Future Directions

B-Cell Lymphomas: Updates and Future Directions

Eduardo Sotomayor, MD

Treatment Conundrums in Myeloma: Whats New in 2022?

Treatment Conundrums in Myeloma: Whats New in 2022?

Sergio Giralt, MD, FACP, FASTCT

Metastatic Colorectal Cancer Therapy

Metastatic Colorectal Cancer Therapy

Richard Kim, MD

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1, and Others in Liquid and Solid Tumor Specimens

Alberto Chiappori, MD

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

Plasma Genotyping in NSCLC: Layering in the Liquid and Future Applications

Benjamin Levy, MD

Stage III NSCLC: Beyond the PACIFIC/ Novel Approaches

Stage III NSCLC: Beyond the PACIFIC/ Novel Approaches

Jorge Gomez, MD

How to Choose Front- Line Therapy for Metastatic NSCLC Without Driver Mutations

How to Choose Front- Line Therapy for Metastatic NSCLC Without Driver Mutations

How to Choose Front- Line Therapy for Metastatic NSCLC Without Driver Mutations

Neo-Adjuvant and Adjuvant Immunotherapy for Non-Small Cell Lung Cancer

Neo-Adjuvant and Adjuvant Immunotherapy for Non-Small Cell Lung Cancer

Luis Raez, MD

Uncommon Mutations/ Fusions: EGFRex20, RET, MET, HER2, NRG1

Uncommon Mutations/ Fusions: EGFRex20, RET, MET, HER2, NRG1

Stephen Liu, MD

Displaying 1,231 - 1,260 of 1,953

«
1
…
40
41
42
43
44
…
66
»

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Userful Links

Live Events

Categories

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok